Clave Capital Finalizes Closing of its €50 Million Healthcare Fund

Clave Capital moves forward. The Navarra-based alternative asset investment manager is finalizing the closing of its fund to invest in early-stage technology transfer projects in the healthcare sector for approximately €50 million, according to sources in the sector.

The vehicle received a commitment of €40 million from the Center for the Development of Industrial Technology (Cdti), through its program for the promotion of business innovation lnnvierte, after a selection process in which eleven management companies participated.

The fund aims to promote the capitalization of technology-based and innovative Spanish companies based on the knowledge generated in research and technology centers. The investment target are profitable projects in disruptive sectors such as Medtech, eHealth, and health-nutrition, among others.

Read more about Clave capital and find the latest updates in the biotech sector with our companion app. Born2Invest’s team of journalists gathers the most interesting business news in a single mobile application. It’s impossible to keep up with everything you’re interested in, but our companion app will help you keep track of the important news. Our app is being updated throughout the day.

Clave Capital is backed by the Government’s Innvierte program

Clave Capital is an independent investment manager founded in 2009, based in Pamplona (Navarra), which currently has more than eighty million euros under management.

The Spanish fund manager has 16 years of experience and has more than sixty investment projects under its belt, participating and getting involved in the value-creation process of the company. Its areas of activity are tech transfer, with €47.27 million under management; growth, with €15.5 million, and energy, with €24.7 million.

Clave Capital specializes in technology transfer projects. Currently, 44% of the €47.27 million invested in this area are earmarked for health tech. The fund manager has more than fifteen investees in the healthcare sector and, in the past, invested in four other companies in the industry.

Clave Capital focuses on innovations linked to research environments and injects capital from the outset

Unlike traditional venture capital, Clave Capital’s model focuses on innovations linked to research environments and injects capital from the outset, even before the company is incorporated.

An example of a company in which Clave Capital has invested is Abanza, a company that specialized in the development of orthopedic devices in the field of traumatology and soft tissue repair.

Another example is a caps, a company that produces new encapsulation technologies for the industrial development of nanocapsules and biocapsules that improve the bioavailability of products, achieving the protection and enhancement of active ingredients, with greater efficacy and stability.

__

(Featured image by moerschy via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.